TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27390979
Drug: Trimetazidine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (35 mg tablet/twice daily for 4 days)
Study: 19579590
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum levels of TPA (cut off level = 53 IU/L) after liver resection
Study: 19579590
Drug: Preoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative serum levels of TPS (cut off level = 81 IU/L) after liver resection
Study: 17505265
Drug: Interferon alpha2b
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha2b 10 million units/m(2) subcutaneously three times a week plus rh-Endostatin 45 mg/m(2) subcutaneously every 12 h (arm A)
Study: 15370023
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment in a specialist clinic
Study: 15370023
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment in a shared care setting
Study: 11462292
Drug: SonoVue (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue (0.3, 0.6, 1.2, and 2.4 mL intravenous bolus injection)
Study: 9740292
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate at a dose of 20 mg/kg/day for 20 days (group A)
Study: 9740292
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate at a dose of 20 mg/kg/day for 30 days (group B)
Study: 27044854
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 70 mg/kg
Study: 23986157
Drug: 6% salicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% salicylic acid cream
Study: 18754533
Drug: Low power
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low power laser (LPL) therapy (9‐11 joules/cm2) over the carpal tunnel area
Study: 12911781
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with Alutard(R)‐SQ, Dermatophagoides pteronyssinus extract, administered with increasing doses until maintenance dose reached, then once a month for 12 months.
Study: 12911781
Drug: Placebo preparation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation, identical to the active preparation.
Study: 10575594
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ipriflavone orally daily
Study: 10575594
Drug: 20 units
Normalized name: Omnipod GO 20 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 units elcatonin, weekly injected intramuscularly
Study: 8767354
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg effervescent tablet
Study: 8767354
Drug: Al-Mg-hydroxide 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Al-Mg-hydroxide 10 ml
Study: 1901321
Drug: Fleroxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (600 mg/d for 72 hours)
Study: 7125177
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine base (2.63 mg morphine hydrochloride) in 10 ml 0.9% sodium chloride
Study: 7125177
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg morphine base in 10 ml 5% glucose
Study: 7125177
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 5% glucose as placebo
Study: 19524752
Drug: Real interferential
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real interferential therapy (IFT), 12 sessions for 4 weeks
Study: 19524752
Drug: Placebo interferential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo interferential therapy (IFT), 12 sessions for 4 weeks
Study: 14616423
Drug: Sublingual cobalamin
Normalized name: mecobalamin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual cobalamin (500 micro g daily)
Study: 14616423
Drug: Oral cobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cobalamin (500 micro g daily)
Study: 14616423
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B complex (two tablets daily)
Study: 9038554
Drug: Continuous postoperative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous postoperative femoral nerve block with 0.5% bupivacaine (5 ml/h for 48 h) plus PCA with morphine
Study: 1824621
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with phenprocumarol
Study: 1824621
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with acetylsalicylic acid (ASA) plus dipyridamole
Study: 24237035
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ATRA given 1 hour before and for 7 days following oral typhoid vaccine
Study: 10517767
Drug: Immunocal (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocal (20 g/day)
Study: 8915874
Drug: Bivalent attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent attenuated cold‐recombinant (CR) vaccine
Study: 8915874
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent subvirion vaccine (TIV)
Study: 2065463
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg clopamide
Study: 6344309
Drug: Pindolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2.5 mg)
Study: 6344309
Drug: Terbutaline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.5 mg subcutaneous) after propranolol and pindolol
Study: 17290057
Drug: Vinblastine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine (5 mg/m2/dose) and Methotrexate (30 mg/m2/dose), administered weekly for 26 weeks and every other week for an additional 26 weeks.
Study: 22449204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and heparin
Study: 9628448
Drug: Novel antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel antithrombotic treatments (direct thrombin inhibitors, platelet fibrinogen receptor antagonists, low-molecular-weight heparins)
Study: 30111291
Drug: Transdiagnostic occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic occupational rehabilitation intervention based on Acceptance and Commitment Therapy (3½ weeks duration)
Study: 27030504
Drug: Autologous dental
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dental pulp stem cell therapy (up to 10 million cells)
Study: 27030504
Drug: Autologous dental
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dental pulp stem cell therapy (maximum tolerable dose)
Study: 27030504
Drug: Autologous dental
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dental pulp stem cell therapy combined with 9 weeks of intensive task-specific rehabilitation
Study: 25319228
Drug: Silexan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan (1 × 160 mg/day)
Study: 19200613
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/d for 4 weeks
Study: 19200613
Drug: Ezetimibe 20
Normalized name: atorvastatin-ezetimibe 20 mg-10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 20 mg/d for 4 weeks
Study: 1791224
Drug: Peptide T
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide T (D‐ala1‐peptide T amide) infused at 10(‐7) mol/L
Study: 31564512
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg once daily for 6 days
Study: 31564512
Drug: Water without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water without any drug (negative control)
Study: 27769609
Drug: High cardiorespiratory
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cardiorespiratory fitness (CRF) defined as VO2peak >27.5 mL/kg/min in women and >34.4 mL/kg/min in men
Study: 20828455
Drug: Natural drying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural drying without a topical regimen
Study: 20828455
Drug: Cleansing with
Normalized name: Eucerin Hydrating Cleansing With Hyaluronic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing with 95% alcohol after daily bathing
Study: 17845862
Drug: Subcutaneous carbon
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous carbon dioxide insufflations
Study: 10965615
Drug: Ulinastatin (600,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (600,000 units in priming solution, 300,000 units in bypass circuit, 300,000 units daily for 5 days post-surgery)
Study: 9047091
Drug: Metformin (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.7 g daily for 4 days)
Study: 8418166
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of an RSV subunit vaccine composed primarily of F glycoprotein
Study: 3097693
Drug: L-tryptophan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (3 g)
Study: 30279397
Drug: DHA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich fish oil supplement (EPAX: 1600 mg DHA + 400 mg EPA)
Study: 28977255
Drug: Maximum stepwise
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum stepwise alveolar recruitment associated with PEEP titration (ART strategy)
Study: 22929542
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (ARDSNet strategy)
Study: 23441920
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy plus azithromycin (AZ-Sca)
Study: 23441920
Drug: Non-surgical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical therapy plus placebo (PB-Sca)
Study: 19055289
Drug: Compound anesthesia
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound anesthesia of transcutaneous electrical point stimulation and Remifentanil
Study: 11073741
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/day; maximum, 500 mg/day)
Study: 11073741
Drug: Ceftriaxone (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (75 mg/kg/day; maximum, 2.5 g/day)
Study: 31909417
Drug: Antibiotic indication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic indication documentation during order entry
Study: 31909417
Drug: Antibiotic indication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic indication documentation for prophylaxis
Study: 31909417
Drug: Antibiotic indication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic indication documentation for empiric antibiotics
Study: 31909417
Drug: Antibiotic indication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic indication documentation for definitive antibiotics
Study: 30835308
Drug: Integrated collaborative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated collaborative care intervention (n=204) including behavioral weight loss treatment, problem-solving therapy, and as-needed antidepressant medications
Study: 28116579
Drug: Brief intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief intervention involving four group sessions of motivational interviewing and cognitive behavioural therapy, initiated 4 weeks prior to release.
Study: 25323237
Drug: Nitrogen dioxide
Normalized name: carbon dioxide / nitrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen dioxide exposure (10 μg · m(‐3))
Study: 25323237
Drug: PM10 exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM10 exposure (10 μg · m(‐3))
Study: 25323237
Drug: PM2.5 exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM2.5 exposure (5 μg · m(‐3))
Study: 24428857
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (15 mg/kg body weight, 100 mg/mL)
Study: 17418728
Drug: 6% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethyl starch (200/0.5) solution to bring down the hematocrit to 45%
Study: 12060503
Drug: Doublebase (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublebase (novel hydro-gel emollient)
Study: 2515215
Drug: Active patch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active patch (N = 11)
Study: 2515215
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (N = 9)
Study: 326447
Drug: Control (dummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (dummy preparation)
Study: 27521672
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DXI; Ozurdex) in combination with ranibizumab (Lucentis)
Study: 24932567
Drug: Behavioral skills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral skills maintenance treatment (BSM)
Study: 22011511
Drug: Carisbamate 200
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 200 mg twice-daily
Study: 22011511
Drug: Carisbamate 600
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 600 mg twice-daily
Study: 17180159
Drug: Tomato-based food
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 6 months by HCV patients
Study: 17180159
Drug: Tomato-based food
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 1 week by healthy subjects
Study: 15530294
Drug: Salicylic-acid cream
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylic-acid cream alone
Study: 11797074
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nicotine
Study: 9549664
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation (CF) venlafaxine 50 mg
Study: 9549664
Drug: Extended-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release formulation (XR) venlafaxine 75 mg
Study: 9549664
Drug: Intravenous venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous venlafaxine 10 mg
Study: 2659953
Drug: Calcitriol 2
Normalized name: CALCITRIOL 2MCG/ML INJ,1ML AMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 2 mcg/d for 7 days, followed by 100 U/d Salmon Calcitonin + 1 g/d Calcitonin for 21 days, followed by Calcium alone for 2 months
Study: 25569408
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (0.5 mg/kg)
Study: 22938659
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid management (25-35 ml×kg(‐1)×d(‐1))
Study: 22938659
Drug: Traditional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional fluid management (40-50 ml×kg(‐1)×d(‐1))
Study: 17989993
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ethanol and 2-propanol disinfectants
Study: 9892878
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 4 days
Study: 9892878
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 7 days
Study: 9892878
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 10 days
Study: 7740846
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms L-thyroxine injected intraamniotically
Study: 1723379
Drug: Salmeterol 100
Normalized name: fluticasone-salmeterol 100 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 100 micrograms inhaled twice daily
Study: 1723379
Drug: Regular beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular beta 2‐agonist therapy
Study: 6126423
Drug: Cimetidine 1000
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1000 mg/day
Study: 6126423
Drug: Oxmetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine 800 mg/day
Study: 30893150
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy for high-grade liposarcoma and leiomyosarcoma of the retroperitoneum in the upcoming STRASS-2 study
Study: 16911869
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg dry powder inhalation twice daily for 8 weeks
Study: 15038626
Drug: Antihypertensive agent
Normalized name: Antihypertensive agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive agent therapy (AHA)
Study: 9625400
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg, once daily at bedtime)
Study: 8174730
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily for 3 months
Study: 30376086
Drug: mOPV2 (challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: mOPV2 (challenge dose)
Study: 26333543
Drug: EBFR of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBFR of 200 mL/min
Study: 26333543
Drug: EBFR of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBFR of 300 mL/min
Study: 26333543
Drug: EBFR of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBFR of 200, 300 and 400 mL/min
Study: 18783971
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg kg(‐1) at induction, 1 mg kg(‐1) h(‐1) during surgery, then 1 mg kg(‐1) during 24 h; n=42)
Study: 15272090
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy and sertraline
Study: 9827437
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of baclofen
Study: 7967424
Drug: High quality
Normalized name: COCONUT OIL 5 g in 30 mL TOPICAL OIL [High Quality Natural Rosemary]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High quality radiation therapy (CESS 86)
Study: 3191933
Drug: Defibrotide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (single infusion)
Study: 25850975
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily
Study: 18647845
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine gel
Study: 31465791
Drug: Placebo (intraurethral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intraurethral aqueous gel)
Study: 23731775
Drug: Candesartan 8mg
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8mg once daily for 3-6 weeks before ECV and 16mg once daily for 6 months after ECV
Study: 8874455
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (CMT) with radiotherapy, 5-fluorouracil (1000 mg/m2 for 4 days or 750 mg/m2 for 5 days), and mitomycin (12 mg/m2 on day 1 of the first course)
Study: 3136331
Drug: sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (250 mg per day)
Study: 26159014
Drug: Qi benefiting
Normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qi benefiting blood activating method (QB-BAM) with Shengmai Injection and Tanshinone IIA Injection
Study: 26159014
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for AECOPD
Study: 25153084
Drug: Once-daily protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC)
Study: 25153084
Drug: Once-daily non-nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) regimen (EFV+FTC/TDF)
Study: 25153084
Drug: Twice-daily NNRTI/NRTI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily NNRTI/NRTI regimen (EFV+3TC/ZDV)
Study: 25153084
Drug: Pill-count non-adherence
Normalized name: Tavist Non-Sedating Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill-count non-adherence
Study: 15180172
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment with Otovowen (fixed combination of plant‐based tinctures and homeopathic potencies)